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Abstract Cardiovascular disease is among the main causes
of morbidity and mortality in developed countries. The
pathological process of the heart is associated with altered
expression profile of genes that are important for cardiac
function. MicroRNAs (miRNAs) have emerged as one of the
central players of gene expression regulation. The implica-
tions of miRNAs in the pathological process of cardiovas-
cular system have recently been recognized, representing the
most rapidly evolving research field. Here, we summarize
and analyze the currently available data from our own
laboratory and other groups, providing a comprehensive
overview of miRNA function in the heart, including a brief
introduction of miRNA biology, expression profile of
miRNAs in cardiac tissue, role of miRNAs in cardiac
hypertrophy and heart failure, the arrhythmogenic potential
of miRNAs, the involvement of miRNAs in vascular
angiogenesis, and regulation of cardiomyocyte apoptosis by
miRNAs. The target genes and signaling pathways linking
the miRNAs to cardiovascular disease are highlighted. The
applications of miRNA interference technologies for manip-
ulating miRNA expression, stability, and function as new
strategies for molecular therapy of human disease are
evaluated. Finally, some specific issues related to future
directions of the research on miRNAs relevant to cardiovas-
cular disease are pinpointed and speculated.
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Introduction
MicroRNAs (miRNAs) have emerged as one of the central
players of gene expression regulation. While the role of
miRNAs in oncogenesis and cardiac development has been
well appreciated over the past few years, the implications of
miRNAs in the pathological process of cardiovascular
system have only been recognized very recently [1–6].
The research on miRNAs in relation to cardiovascular
disease has become a most rapidly evolving field. Several
excellent review articles and editorial commentaries on this
subject have been published lately [1–6]. Here, we do not
attempt to repeat the contents and thoughts appearing in
these papers. Instead, we try to summarize and analyze the
currently available data from our own laboratory and other
groups, providing a comprehensive overview of miRNAs
and cardiovascular disease. The functional role of miRNAs
in cardiac development and cardiovascular disease of adult
hearts (including cardiac hypertrophy, heart failure, arrhyth-
mias, cardiomyocyte apoptosis, vascular angiogenesis) and
the target genes and signaling pathways linking these
miRNAs to the events will be discussed. The applications
of miRNA interference technologies for manipulating
miRNA expression, stability, and function as new strategies
for molecular therapy of human disease will be evaluated.
Finally, some specific issues related to future directions of
the research on miRNAs relevant to cardiovascular disease
will be pinpointed and speculated [1–6].
miRNA biology
miRNAs are initially transcribed as long RNA precursors
called primary miRNAs that requires the RNase III enzyme
Drosha in the nucleus to be trimmed into premature
miRNAs. The latter precursor, characterized by a 33-
nucleotide (nt) stem-loop or hairpin structure of 60–70 nts,
are exported to the cytoplasm where they are subsequently
cropped to become mature miRNAs of 21–26 nts in length,
by another RNase III enzyme Dicer [7–11].
Mature miRNAs can interact with Argonaute to form the
RNA-induced silencing complex (RISC) and then guide the
RISC to their target mRNAs, most favorably to the 3'-
untranslated region (3'UTR). In order for a miRNA to
produce functional consequences, its 5'-end 7 to 8 nts must
have exact base pairing to the target mRNA, the “seed”
region, and partial complementarity with the rest of the
sequence. An miRNA can either inhibit translation or
induce degradation of its target mRNA, primarily depend-
ing upon the overall degree of complementarity of the
binding site, number of binding sites, and the accessibility
of the bindings sites (determined by free energy states). The
greater the complementarity of the accessible binding sites,
the more likely an miRNA degrades its targeted mRNA,
and those miRNAs that display imperfect sequence com-
plementarities with target mRNAs primarily result in
translational inhibition [12–17]. The more accessible the
binding sites for an miRNA, the greater the actions of that
miRNA owing to the potential cooperative miRNA–mRNA
interactions from different sites. It is noteworthy that the
finding by a most recent study that miRNAs can also act to
enhance translation when AU-rich elements and miRNA
target sites coexist at proximity in the target mRNA and
when the cells are in the state of cell-cycle arrest [18]. It is
proposed that translation regulation by miRNAs oscillates
between repression and activation during the cell cycle.
MiRNAs are an abundant RNA species constituting >3%
of the predicted human genes, which regulates ~30% of
protein-coding genes [19]. The high sequence conservation
across metazoan species suggests strong evolutionary
pressure and participation of miRNAs in essential biologic
processes such as cell proliferation, differentiation, apopto-
sis, metabolism, stress, etc. [20, 21]. It has been predicted
that each single miRNA can have >1,000 target genes and
each single protein-coding gene can be regulated by
multiple miRNAs [22, 23]. This is simply because the
actions of miRNAs are sequence or motif specific but not
gene specific; different genes can have similar binding
motifs for a given miRNA and a given gene can have the
binding motifs for distinct miRNAs.
Expression profile of miRNAs in the heart
The expression profile of miRNAs appears to be tissue–cell
specific. This implies that a group of miRNAs express only
in a certain tissue–cell type or different groups of miRNAs
expressed in different tissues–cells. For example, the
miRNA expression profile in artery is different from that
in heart. The most abundant miRNAs in cardiac muscles
are miR-1, let-7, miR-133, miR-126-3p, miR-30c, and miR-
26a [24]. However, in artery smooth muscles, the most
abundant miRNAs are miR-145, let-7, miR-125b, miR-
125a, miR-23, and miR-143, though miR-1 and miR-133 are
also expressed in artery smooth muscles [25]. The
differential tissue distributions of miRNAs suggest tissue-
or even cell-type-specific function of these molecules.
The expression profile of miRNAs is also disease status
dependent. A particular pathological process is associated
with the expression of a particular group of miRNAs, a
signature expression pattern of miRNAs. These signature
patterns could aid in the diagnosis and prognosis of human
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cardiovascular disease, human cancer, and other disorders.
Among >500 miRNAs identified thus far in mamma-
lians, miR-1, miR-133, and miR-208 are considered muscle
specific, being primarily expressed in cardiac and skeletal
muscles [17, 26–32]. The miR-1 family is comprised of the
miR-1 subfamily and miR-206, with the former subfamily
consisting of two transcripts, miR-1-1 and miR-1-2, that
possess an identical mature sequence but are encoded by
distinct genes located on chromosomes 2 and 18, respec-
tively. The miR-133 family is comprised of miR-133a-1,
miR-133a-2, and miR-133b, with miR-133a expressed from
bicistronic units together with the miR-1 subfamily and
miR-133b together with miR-206 [26, 27]. The resulting
mature products from the miR-133 family are either
identical or have only 1-nt difference. miR-208 is encoded
by an intron in the α-myosin heavy chain (MHC) gene
[32]. Cardiac-muscle-specific expressions of miR-1 and
miR-133 are controlled by serum responsive factor (SRF)–
myocardin and of miR-208 are associated with expression
of α-MHC gene. A recent study indeed confirmed that
>90% of miR-1 transcripts were blocked in the SRF
knockout hearts [33]. By comparison, skeletal-muscle-
specific expressions of miR-1 and miR-133 are controlled
by myogenic differentiation–myocyte enhancer factor 2
(MEF2). A most recent study further revealed that MEF2
directly activates transcription of miR-1-2 and miR-133a-1
cluster and of miR-1-1 and miR-133a-2 locus as well [34].
These data suggest that the tissue-specific expressions of
miRNAs are largely determined by transcription factors.
miRNAs and cardiac development
Heart malformations occur in as high as 1% of newborns,
presenting a significant clinical problem in our modern world.
The muscle-specific miRNAs are expressed in the early
stages during cardiogenesis. Microarray analysis revealed an
increased expression of miR-1 and miR-133 in developing
mouse hearts from embryonic day (E)12.5 through to at least
E18.5, indicating a requirement of these miRNAs for cardiac
development [26]. Several lines of evidence have been
obtained in support of this notion [17, 26].
Block of miRNA biogenesis by tissue-specific deletion
of Dicer causes lethality of embryos due to defects in
cardiogenesis. When Dicer was efficiently deleted in the
heart, death of the embryos by E12.5 due to cardiac failure
was consistently observed [29]. Dicer-deficient embryos
developed cardiac failure due to pericardial edema and
underdevelopment of the ventricular myocardium. These
phenotypes are in agreement with the defects of heart
development in zebrafish embryos devoid of Dicer function
[35].
Studies using both “gain-of-function” and “loss-of-
function” approaches point to the roles of miR-1 and miR-
133 in modulating cardiogenesis and in maintenance of
muscle–gene expression. Genetic engineering in Drosoph-
ila demonstrated that miR-1 may “fine-tune” Notch ligand
Delta that is critically involved in differentiation of cardiac
and somatic muscle progenitors and targets a pathway
required for progenitor cell specification and asymmetric
cell division [28]. In Xenopus laevis, injection of either
miR-1 at one-cell stage results in complete absence of
cardiac tissue [26]. On the other hand, introduction of miR-
133 allows cardiac tissue to form, but the tissue is
disorganized and does not lead to chamber formation. The
authors of this study proposed that both miR-1 and miR-133
are required for proper heart development and they may
have distinct roles with miR-1 promoting myogenesis while
miR-133 enhancing myoblast proliferation.
In mouse, miR-1 is responsible for the inhibition of
cardiomyocyte progenitor proliferation via inhibition of
translation of Hand2 [17], a transcription factor known to
regulate ventricular cardiomyocyte expansion [36]. Over-
expression of miR-1 in a transgenic mouse model resulted
in a phenotype characterized by thin-walled ventricles,
attributable to premature differentiation and early with-
drawal of cardiomyocytes from the cell cycle [29]. In
contrast, many of the embryos from miR-1-2 knockout mice
demonstrated ventricular septal defects in a subset that
suffer early lethality. The adult miR-1-2-deficient mice had
thickened chamber walls attributable to hyperplasia of the
heart [29].
miRNAs and cardiac hypertrophy and heart failure
In response to stress (such as hemodynamic alterations
associated with myocardial infarction, hypertension, aortic
stenosis, valvular dysfunction, etc), the adult heart under-
goes remodeling process and hypertrophic growth to adapt
to altered workloads and to compensate for the impaired
cardiac function. Hypertrophic growth manifests enlarge-
ment of cardiomyocyte size and enhancement of protein
synthesis through the activation of intracellular signaling
pathways and transcriptional mediators in cardiac myo-
cytes. The process is characterized by a reprogramming of
cardiac gene expression and the activation of “fetal” cardiac
genes [37]. In light of the role of miRNAs in cardiac
development, one has a good reason to believe an
involvement of miRNAs in cardiac hypertrophy. It is thus
not surprising to see that this topic has indeed become an
intensively studied subject; within a year from late 2006 up
to now, there have been seven published original research
articles focused on miRNAs and cardiac hypertrophy–heart
failure. The findings from these studies reveal an important
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growth and chamber remodeling of the heart and point to
miRNAs as potential therapeutic targets in heart disease.
These studies reported some common findings but also
presented some controversies.
The first common finding is that an array of miRNAs is
significantly altered in their expression, either upregulated
or downregulated, and studies from different research
groups demonstrated overlapping miRNAs that are altered
in cardiac hypertrophy. The second common finding is that
single miRNAs can critically determine the progression of
cardiac hypertrophy. Olson's [38] group reported >12
miRNAs that are upregulated or downregulated in cardiac
tissue from mice in response to transverse aortic constric-
tion (TAC) or expression of activated calcineurin, stimuli
that induce pathological cardiac remodeling. Many of these
miRNAs were found similarly regulated in failing human
hearts. Forced overexpression of stress-inducible miRNAs
induced hypertrophy in cultured cardiomyocytes. Particu-
larly, overexpression of miR-195 alone, which was upregu-
lated during cardiac hypertrophy, was sufficient to induce
pathological cardiac growth and heart failure in transgenic
mice. However, the target genes for miR-195 relevant to
hypertrophy have not been studied. The same group
recently found that miR-208, encoded by an intron of the
α-MHC gene, is required for cardiomyocyte hypertrophy,
fibrosis, and expression of β-MHC in response to stress and
hypothyroidism [32]. The study showed that miR-208
mutant mice failed to undergo stress-induced cardiac
remodeling, hypertrophic growth, and β-MHC upregula-
tion, whereas transgenic expression of miR-208 was
sufficient to induce β-MHC. miR-208 regulates β-MHC
by repressing the thyroid hormone receptor associated
protein 1, a cofactor of the thyroid hormone receptor and
a predicted miR-208 target mRNA. Abdellatif's [39]g r o u p
reported an array of miRNAs that are differentially and
temporally regulated during cardiac hypertrophy. They found
that miR-1 was singularly downregulated as early as day 1,
persisting through day 7, after TAC-induced hypertrophy in a
mouse model. Overexpression of miR-1 carried by adenovi-
rus vector inhibited its in silico-predicted growth-related
targets, including Ras guanosine-triphosphatase-activating
protein, cyclin-dependent kinase 9, fibronectin, and Ras
homolog enriched in brain, in addition to protein synthesis
and cell size. Their study also suggests that miRNA
expression profiles at different time points after TAC are
different, with expression of >50 miRNAs progressively
changing during development of pressure overload cardiac
hypertrophy. Thus, they proposed that miRNAs play an
essential regulatory role in the development of cardiac
hypertrophy, wherein downregulation of miR-1 is necessary
for the relief of growth-related target genes from its
repressive influence and induction of hypertrophy. A study
from Condorelli's group focuses on the role of miR-133 and
miR-1 in cardiac hypertrophy with three murine models:
TAC mice, transgenic mice with selective cardiac over-
expression of a constitutively active mutant of the Akt
kinase, and human tissues from patients with cardiac
hypertrophy [40]. They first showed that cardiac hypertro-
phy in all three models resulted in reduced expression
levels of both miR-133 and miR-1 in the left ventricle. They
then described that in vitro overexpression of miR-133 or
miR-1 inhibited cardiac hypertrophy. In contrast, suppres-
sion of miR-133 induced hypertrophy, which was more
pronounced than that after stimulation with conventional
inducers of hypertrophy. In vivo inhibition of miR-133 by a
single infusion of an antimiRNA antisense oligonucleotide
(AMO) against miR-133 caused marked and sustained
cardiac hypertrophy. They then identified specific targets
of miR-133: RhoA, a guanosine diphosphate–guanosine
triphosphate exchange protein regulating cardiac hypertro-
phy; Cdc42, a signal transduction kinase implicated in
hypertrophy; and Nelf-A/WHSC2, a nuclear factor in-
volved in cardiogenesis. Cheng et al. [41] identified 19
deregulated miRNAs in hypertrophic mouse hearts after
aortic banding. Knockdown of miR-21 expression via
AMO-mediated depletion had a significant negative effect
on cardiomyocyte hypertrophy induced by TAC in mice or
by angiotensin II or phenylephrine in cultured neonatal
cardiomyocytes. Consistently, another independent group
identified 17 miRNAs upregulated and three miRNAs
downregulated in TAC mice and seven upregulated and
four downregulated in phenylephrine-induced hypertrophy
of neonatal cardiomyocytes. They further showed that
inhibition of endogenous miR-21 or miR-18b that are most
robustly upregulated augments hypertrophic growth, while
introduction of either of these two miRNAs into cardio-
myocytes represses cardiomyocyte hypertrophy [42]. A
study directed to the human heart identified 67 significantly
upregulated miRNAs and 43 significantly downregulated
miRNAs in failing left ventricles versus normal hearts [43].
Interestingly, 86.6% of induced miRNAs and 83.7% of
repressed miRNAs were regulated in the same direction in
fetal and failing heart tissue compared with healthy hearts,
consistent with the activation of “fetal” cardiac genes in
heart failure. Bioinformatics analysis revealed that the
mRNAs upregulated in the failing heart contain the putative
binding sites for the downregulated miRNAs and vice
versa. Most strikingly, transfection of cardiomyocytes with
a set of fetal miRNAs induced cellular hypertrophy as well
as changes in gene expression comparable to the failing
heart. The above findings are summarized in Fig. 1.
It should be noted that controversies exist among these
studies. Probably the most striking disparity is the contra-
dictory results from the studies reported by Cheng et al.
[41] and Tatsuguchi et al. [42]. Cheng et al. showed that
774 J Mol Med (2008) 86:771–783knockdown of miR-21 relieves cardiomyocyte hypertrophy
[41], whereas the study from Wang's [42] group demon-
strated the opposite. Both studies used the phenylephrine
model of hypertrophy in cultured neonatal rat ventricular
myocytes. The study by Carè et al. [40] clearly indicates
that miR-133 is an antihypertrophic factor and down-
regulation of miR-133 alone is sufficient to induce cardiac
hypertrophy. However, the study reported by van Rooij et
al. [38] suggests that miR-133 does not cause any
morphological changes of cardiomyocytes indicative of
hypertrophic growth. Moreover, among the seven studies,
two [38, 40] reported downregulation of miR-133 in
hypertrophy, three [39, 41, 43] failed to observe this
change, one found it upregulated [42], and another study
did not deal with miR-133 [32]. While miR-1 was found to
be downregulated in two studies [39, 40], this observation
was not reproduced in three other studies [38, 41, 42] and
one study performed with human heart actually claimed
it to be upregulated [43]. Increase in miR-18b was seen
only in one study [42]. The most consistent changes
reported by the six studies are upregulation of miR-21 (six
of six studies), miR-23a (four of six), miR-125b (five of
six), and miR-214 (four of six) and downregulation of miR-
150 (five of six studies) and miR-30 (five of six). The
discrepancies could be explained by multiple factors,
including different models of hypertrophy, different time
points of the same models, different miRNA microarrays
for analyses, etc.
Collectively, with respect to hypertrophy, it is evident
that in addition to the muscle-specific, miRNAs miR-1,
miR-133, and miR-208, other miRNAs, including miR-195,
miR-21, miR-18b, etc, also play an important role. It
appears that multiple miRNAs are involved in cardiac
hypertrophy and each of them can independently determine
the pathological process.
miRNAs and cardiac arrhythmias
Arrhythmias are electrical disturbances that can result in
irregular heart beating with consequent insufficient pump-
ing of blood. Arrhythmias are often lethal, constituting a
major cause for cardiac death in myocardial infarction and
heart failure and being one of the most difficult clinical
problems [44]. Arrhythmias can occur when there is
abnormality in the electrical activities: cardiac conduction,
repolarization, or automaticity. The electrical activities of
the heart are determined by ion channels, the transmem-
brane proteins embedded across the cytoplasmic membrane
of cardiomyocytes. Sodium channels and connexin43
(Cx43) are responsible for excitation generation and
intercell conduction of excitations, respectively. Calcium
channels account for excitation–contraction coupling and
also contribute to pacemaker activities. Potassium channels
govern the membrane potential and rate of membrane
repolarization. Pacemaker channels, which carry the non-
selective cation currents, are critical in generating sinus
rhythm and ectopic heart beats as well. Intricate interplays
of these ion channels maintain the normal heart rhythm.
Dysfunction of any of the ion channels can render
arrhythmias (Fig. 2).
We conducted bioinformatics analysis using miRNA
database websites miRBase and miRANDA to predict the
potential target genes encoding cardiac ion channel proteins
for the muscle-specific miRNAs miR-1, miR-133, and miR-
208. Based on the information, we then carried out
Fig. 1 Diagram depicting the miRNAs, along with their target genes,
which have been experimentally evidenced for their participation in
the development of cardiac hypertrophy. THRAP1 thyroid hormone
receptor associated protein 1; RasGAP Ras GTPase-activating protein;
Cdk9 cyclin-dependent kinase 9; Rheb Ras homolog enriched in brain;
RhoA, a GDP–GTP exchange protein regulating cardiac hypertrophy;
Cdc42, a signal transduction kinase; and Nelf-A/WHSC2, a nuclear
factor involved in cardiogenesis. These proteins have been implicated
in hypertrophy
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targets. From these studies, we are able to obtain an overall
picture of expression regulation of ion channel genes by the
muscle-specific miRNAs and to come up with the follow-
ing notes. First, while miR-1 and miR-133 both can regulate
multiple genes that cover nearly all cardiac ion channel
subunits, miR-208 does not seem to have any ion channel
genes as its target for posttranscriptional repression.
Second, miR-1 or miR-133 each has its distinct set of ion
channel targets without overlapping genes for both, except
for the pacemaker channel gene HCN2 that is regulated by
both miR-1 and miR-133 (unpublished observations). Third,
some computationally predicted targets failed to be exper-
imentally verified but some nonpredicted genes were found
to be targets for miR-1 or miR-133 according to our
experimental results.
It has been commonly accepted that regional dispersion
of ventricular repolarization is a marker of arrhythmoge-
nicity risk [45, 46]. The spatial heterogeneity of cardiac
repolarization is largely due to diversity and varying
densities of repolarizing K
+ currents [47–49]. Slowly
activating delayed rectifier K
+ current (IKs) along with its
underlying channel proteins KCNQ1 (pore-forming α-
subunit) and KCNE1 (auxiliary β-subunit) demonstrates
important spatial heterogeneity of distribution, contributing
importantly to arrhythmogenicity [50]. We have experimen-
tally established KCNQ1 and KCNE1 as targets for repres-
sion by miR-133 and miR-1,r e s p e c t i v e l y( F i g .2)[ 51]. More
importantly, we found that the distribution of miR-133 and
miR-1 transcripts within the heart is also spatially heteroge-
neous with the patterns corresponding to the spatial
distribution of KCNQ1 and KCNE1 proteins and IKs.
Abnormal QT interval prolongation is a prominent
electrical disorder and has been proposed a predictor of
mortality in patients with diabetes mellitus, presumably
because it is associated with an increased risk of sudden
cardiac death consequent to lethal ventricular arrhythmias
[52, 53]. We have previously found that the ether-a-go-go-
related gene (ERG), a long QT syndrome gene encoding a
key K
+ channel (IKr) in cardiac cells, is severely depressed
in its expression at the protein level but not at the mRNA
level in diabetic subjects [54]. In an effort to understand the
mechanisms underlying the disparate alterations of ERG
protein and mRNA, we performed a study on expression
regulation of ERG by miRNAs in a rabbit model of
diabetes [55]. We found a remarkable overexpression of
miR-133 in diabetic hearts and, in parallel, the expression of
SRF, which is known to be a transactivator of miR-133, was
also found robustly increased. Delivery of exogenous miR-
133 into the rabbit myocytes and cell lines produced
posttranscriptional repression of ERG, downregulating
ERG protein level without altering its transcript level.
Correspondingly, forced expression of miR-133 also caused
substantial depression of IKr, an effect abrogated by the
miR-133 antisense inhibitor. Functional inhibition or gene
silencing of SRF downregulated miR-133 expression and
increased IKr density. Repression of ERG by miR-133 likely
underlies the differential changes of ERG protein and
transcript thereby depression of IKr and contributes to
repolarization slowing thereby QT prolongation and the
associated arrhythmias in diabetic hearts (Fig. 2).
One of the most deleterious alterations during myocar-
dial infarction is the occurrence of ischemic arrhythmias
[56]. We found that miR-1 is overexpressed (~2.8-fold
Fig. 2 Schematic illustration of the role of the muscle-specific
miRNAs miR-1 and miR-133 in arrhythmias. Cx43 connexin-43; IK1
inward rectifier K+ current; IKr rapid delayed rectifier K+ current; IKs
slow delayed rectifier K+ current; If pacemaker nonselective cation
current or funny current; Kir2.1 a pore-forming K+ channel α-subunit
for IK1; HERG a pore-forming K+ channel α-subunit for IKr; KCNQ1
a pore-forming K+ channel α-subunit for IKs; KCNE1 an auxiliary β-
subunit for IKs; HCN2 and HCN4 α-subunits for If; APD action
potential duration; ERP effective refractory period; EAD early after
depolarization
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artery disease relative to healthy hearts. To explore the
mechanisms, we used a rat model of myocardial infarction
induced by occlusion of the left anterior descending
coronary artery for 12 h that corresponds to the peri-
infarction period during which phase II ischemic arrhyth-
mias often occur, which represents a major challenge to our
understanding and management of the disorder [57]. We
found a similar increase (~2.6-fold) in miR-1 expression in
the ischemic hearts of rat, which was accompanied by
exacerbated arrhythmogenesis [58]. Elimination of miR-1
by an antisense inhibitor in infarcted rat hearts relieved
arrhythmogenesis. miR-1 overexpression slowed cardiac
conduction and depolarized the cytoplasmic membrane,
which is likely the cellular mechanism for the arrhythmo-
genic potential of miR-1. We further established GJA1,
which encodes connexin 43 [59], and KCNJ2, which encodes
the K
+ channel subunit Kir2.1 [60, 61], as target genes for
miR-1. Cx43 is critical for intercell conductance and Kir2.1
for setting and maintaining membrane potential. Repression
of these proteins by miR-1 explains for miR-1-induced
slowing of cardiac conduction. We therefore proposed that
myocardial infarction upregulates miR-1 expression via some
unknown factors, which induces posttranscriptional repres-
sion of GJA1 and KCNJ2, resulting in conduction slowing
leading to ischemic arrhythmias (Fig. 2).
Zhao et al. [29] determined in vivo miR-1-2 targets,
including the cardiac transcription factor, Irx5, which
represses KCND2, a potassium channel subunit (Kv4.2)
responsible for transient outward K
+ current (Ito)[ 62, 63].
Their study suggests that the combined loss of Irx5 and Irx4
disrupted ventricular repolarization with a predisposition to
arrhythmias. The increase in Irx5 and Irx4 protein levels in
miR-1-2 mutants corresponded well with a decrease in
KCND2 expression. Clearly, loss-of-function of miR-1 and
Dicer mutant embryos affect conductivity through K
+
channels which supports a central role for miR-1 for fine
tuning the regulation of cardiac electrophysiology in
pathological and normal conditions.
miRNAs and vascular angiogenesis
It is known that proliferative vascular diseases share similar
cellular events and molecular mechanisms with cancer, and
neointimal lesion formation is the pathological basis of
proliferative vascular diseases. Neointimal growth is the
balance between proliferation and apoptosis of vascular
smooth muscle cells (VSMCs). The increased VSMC
proliferation or the relative decreased VSMC apoptosis
are responsible for neointimal lesion formation. Ji et al. [25]
reported that multiple miRNAs are aberrantly expressed in
the vascular wall after angioplasty with the time course
changes matching the complex process of neointimal lesion
formation, in which multiple genes are accordingly deregu-
lated, as assessed with miRNA microarray. Seven days after
balloon injury, 113 of the 140 artery miRNAs were
differentially expressed (60 miRNAs were upregulated,
and 53 miRNAs were downregulated). At 14 days after
injury, 110 of the 140 artery miRNAs were differentially
expressed (63 up and 47 down), whereas 102 of the 140
artery miRNAs were differentially expressed (55 up and 47
down) at 28 days after angioplasty. Their results indicate
that multiple miRNAs are involved in neointimal lesion
formation, but miR-21 may be of particular significance.
miR-21 was found to be one of the most upregulated
miRNAs in the vascular wall of balloon-injured rat carotid
arteries. Inhibition of miR-21 expression via AMO-mediated
miRNA depletion significantly decreased neointimal forma-
t i o na f t e ra n g i o p l a s t yb yd e c r e asing cell proliferation and
increasing cell apoptosis. Their data further identified phos-
phatase and tensin homolog and Bcl-2 as target genes for miR-
21 in VSMCs. The authors believe that miRNAs may be a
new therapeutic target for proliferative vascular diseases such
as atherosclerosis, postangioplasty restenosis, transplantation
arteriopathy, and stroke [25].
A study by Suárez et al. [64] showed that knockdown of
Dicer by RNA interference (RNAi) techniques in human
endothelial cells (ECs) altered the expression of several key
regulators of endothelial biology and angiogenesis, includ-
ing TEK–Tie-2, kinase insert domain receptor–vascular
endothelial growth factor receptor 2, Tie-1, endothelial
nitric oxide synthase (eNOS), and interleukin-8. The RNAi-
mediated knockdown of Dicer in ECs resulted in a
significant reduction but not complete loss of mature
miRNAs. The net phenotype of Dicer knockdown in ECs
was an increase in eNOS protein levels and NO release and
decrease in EC growth. Forced expression of miR-222 and
miR-221 that were among the highest expressed in ECs
regulates eNOS protein levels after Dicer silencing.
The laboratory of Dimmeler et al. [65] also investigated
the role of Dicer and Drosha in angiogenesis. In their study,
ECs were transfected with small interfering RNA (siRNA)
against Dicer and Drosha to inhibit miRNA biogenesis.
Genetic silencing of Dicer and Drosha significantly reduced
capillary sprouting of ECs and tube-forming activity.
Migration of ECs was significantly decreased in Dicer
siRNA-transfected cells, whereas Drosha siRNA had no
effect. Silencing of Dicer but not of Drosha reduced
angiogenesis in vivo. They then screened 168 human
miRNAs using real-time polymerase chain reaction and
revealed that members of the let-7 family, miR-21, miR-
126, miR-221,a n dmiR-222 are highly expressed in
endothelial cells. Dicer and Drosha siRNA reduced lef-7f
and miR-27b expression. Inhibitors against let-7f and miR-
27b also reduced sprout formation indicating that these
J Mol Med (2008) 86:771–783 777miRNAs promote angiogenesis by targeting antiangiogenic
genes. In silico analysis of predicted targets for let-7 cluster
identified the endogenous angiogenesis inhibitor thrombo-
spondin-1. They confirmed that Dicer and Drosha siRNA
significantly increased the expression of thrombospondin-1.
Their findings indicate that inhibition of Dicer impairs
angiogenesis in vitro and in vivo, whereas inhibition of
Drosha induces only a minor antiangiogenic effect [65].
miRNAs and cardiomyocyte apoptosis
Loss of cardiac myocytes due to apoptotic cell death is
common to myocardial ischemia, cardiac hypertrophy, and
heart failure. Increasing evidence indicates that miRNAs as
apoptosis regulators are also implicated cardiovascular
disease.
We have recently shown that miR-1 level is markedly
elevated in ischemic myocardium where apoptotic cell
death plays an important role in the detrimental changes of
the diseased heart [58]. Coincidently, another study from
our laboratories revealed miR-1 and miR-133 produced
opposing effects on apoptosis induced by oxidative stress in
H9c2 rat ventricular cells, with miR-1 being proapoptotic
and miR-133 being antiapoptotic [66]. miR-1 level was
significantly increased in response to oxidative stress and
this increase reduced the protein levels of the antiapoptotic
molecules heat shock protein-60 (HSP60) [67] and HSP70
[68] without changing their transcript levels. By compari-
son, miR-133 repressed apoptotic caspase-9 [69] expression
at both protein and mRNA levels to favor cell survival. The
posttranscriptional repression of HSP60–HSP70 and cas-
pase-9 was further confirmed by luciferase reporter experi-
ments [66]. Our results therefore suggest that the ischemic
elevation of miR-1 level may contribute to the enhanced
apoptotic cell death in myocardial infarction, in addition to
the enhanced arrhythmogenicity. In another case, we found
that in the heart with cardiomyopathy of diabetic subjects,
miR-133 level is increased [55]. It is speculated that this
increase may serve to protect the heart considering that
miR-133 negatively regulate apoptosis.
Also noteworthy is that among the hypertrophy-inducing
miRNAs, miR-1, miR-133, and miR-21 are known apopto-
sis regulators. Other miRNAs miR-195, miR-18b,a n dmiR-
208 that have been shown to independently regulate
hypertrophy also have the potential to regulate apoptosis,
although experimental data are still missing. According to
our bioinformatics prediction, miR-195 could repress
multiple survival genes including the Bcl-2 gene family,
the E2F gene family, Akt, and NF2, being characteristic of
a proapoptotic regulator. Similarly, miR-18b also has the
potential to regulate multiple antiapoptotic genes, including
Akt, Sp1, Bcl-2, E2F, and IGF1.
miRNA interference technologies and cardiovascular
disease
The role of miRNAs in the pathogenesis of the heart and
vessel points to a possibility of miRNAs as targets for
treatment of cardiovascular disease. To achieve the thera-
peutic goal, strategies for manipulating miRNAs by
influencing their expression, stability, and function are
needed. Such miRNA interference strategies involve both
“gain-of-function” and “loss-of-function” approaches. Sev-
eral innovative technologies have been developed for this
purpose over the past few years.
Supply of artificial miRNAs Some miRNAs are decreased
in their expression levels in cardiovascular tissues and
correction of deregulated expression of these miRNAs by
“replacement therapy” may be an efficient approach for
management of the disorders. Introduction of synthetic
miRNAs into cells as a “gain-of-function” approach has
proven feasible under many conditions.
AntimiRNA antisense inhibitor oligonucleotides techniques
AMOs are artificially designed oligonucleotides fully
complementary to target miRNAs and it acts to breakdown
the targeted miRNAs with unknown mechanisms [51, 55,
58, 70, 71]. In this way, AMO abolishes the action of the
targeted miRNAs. It mediates potent and miRNA-specific
inhibition of miRNA function, providing a powerful “loss-
of-function” strategy for interfering miRNA expression.
When attached with cholesterol moieties to permit entry
into the cell, an AMO is called “antagomirs”. Antagomirs
can be used to bind with unwanted miRNAs and have been
shown to be capable of in vivo silencing expression of
miRNAs in the mouse heart [72]. Today, AMO has become
a necessary tool for miRNA research and has also been
proposed to be potential therapeutic agents as well.
miRNA sponge techniques Ebert et al. [73] invented an
innovative antimiRNA approach termed “miRNA
sponges.” The idea behind it is to produce a single specie
of RNAs containing multiple, tandem-binding sites for a
miRNA seed family of interest, in order to target all
members of that miRNA seed family, taking advantage of
the fact that the interaction between miRNA and target is
nucleated by and largely dependent on base pairing in the
seed region (positions 2–8 of the miRNA). The authors
constructed sponges by inserting tandemly arrayed miRNA
binding sites into the 3'UTR of a reporter gene encoding
destabilized green fluorescent protein driven by the cyto-
megalovirus promoter, which can yield abundant expres-
sion of the competitive inhibitor transcripts. Binding sites
for a particular miRNA seed family were perfectly
complementary in the seed region with a bulge at positions
778 J Mol Med (2008) 86:771–7839–12 to prevent RNA-interference-type cleavage and
degradation of the sponge RNA. When vectors encoding
these miRNA sponges are transiently transfected into
cultured cells, they depress miRNA targets as strongly as
the conventional AMOs. The major advancement of this
technique over the AMO technique is that it can better
inhibit functional classes of miRNAs than do AMOs that
are designed to block single miRNA sequences.
miRNA-masking antisense oligonucleotides techniques It
has been predicted that each single miRNA may regulate as
many as 1,000 protein-coding genes and each gene may be
regulated by multiple miRNAs [23]. This implies that the
action of miRNAs is binding sequence specific but not gene
specific; similarly, the action of AMOs is miRNA specific
but not gene specific either. These properties of miRNAs
and AMOs may present the obstacles for development as
therapeutic agents because they may elicit unwanted side
effects and toxicity due to their non-gene-specific function-
al profiles. To tackle this problem, we have developed a
technique that we term miRNA-masking antisense oligo-
deoxynucleotides (miR-Mask ODN) [74]. We validated this
technology by testing its application to the cardiac
pacemaker channel-encoding genes HCN2 and HCN4.A
miR-Mask is designed to be exactly antisense to the
binding site for an endogenous miRNA of interest in
3'UTR of the target mRNA. Once introduced into the cell,
the miR-Mask can form duplex with the target mRNA with
higher affinity than that endogenous miRNA. In this way,
the miR-Mask acts as a target protector masking the
binding site to block the access of that miRNA to its site
of action with consequent relief of the repressive effect
produced by that miRNA. We have successfully created
miR-Masks that can bind to HCN2 and HCN4 and prevent
the repressive actions of miR-1 and miR-133. These miR-
Masks result in enhanced protein expression of the
pacemaker channels and increased pacemaker activities
revealed by whole-cell patch-clamp recordings. Function-
ally, the miR-Masks for HCN channels cause acceleration
of heart rate in rats, simulating “biological pacemakers”
[75]. The major advantage of this technology is that it
offers a gene-specific miRNA-interfering strategy. This
technology has been validated by a recent study in which
the authors investigated the role of zebrafish miR-430 in
regulating expression of TGF-β nodal agonist squint and
antagonist lefty [76], the key regulators of mesendoderm
induction and left–right axis formation. They designed
target protector morpholinos complementary to miRNA
binding sites in target mRNAs in order to disrupt the
interaction of specific miRNA–mRNA pairs. Protection of
squint or lefty mRNAs from miR-430 resulted in enhanced
or reduced nodal signaling, respectively.
The miR-Mask approach defers from the AMO approach
in several aspects, despite that they both can result in
enhancement of gene expression by removing the repres-
sive effects of a particular miRNA on protein translation of
the target mRNA. First, an AMO is designed to entirely
base pair with the sequence of the target miRNA, whereas a
miR-Mask is designed based on the sequence of the target
site for a miRNA in the 3′UTR of the target mRNA [74].
Second, an AMO interacts with (binds to) its target miRNA
and may well cause degradation of that miRNA such that
all functions of that miRNA are deemed to be impaired,
whereas a miR-Mask interacts with (binds to) its target
mRNA and does not induce miRNA degradation such that
the function of that miRNA on other genes is intact. In this
sense, a miR-Mask is not only a target protector but also a
miRNA protector. Third, the action of an AMO is miRNA
specific but not gene specific and it may well induce
enhancement of expression of multiple genes regulated by
the target miRNA, whereas a miRNA-masking antisense
ODN is expected to be gene specific because it is fully
complementary to the target mRNA sequence and is
miRNA specific as well because it is designed to target
the binding site of that miRNA. Based on the above
discussions, it seems that the miR-Mask approach is a
valuable supplement to the AMO technique; while AMO is
indispensable for studying the overall function of a
miRNA, the miR-Mask might be more appropriate for
studying the specific outcome of regulation of the target
Table 1 Comparisons among miR-Mask, AMO, and conventional antisense ODN
miR-Mask AMO Antisense ODN
Structure RNA or DNA RNA or DNA DNA
Targeting mRNA (3′UTR) miRNA mRNA (CdR)
Specificity mRNA specific (gene specific) miRNA specific (non-gene specific) mRNA specific (gene specific)
Mode of Action miRNA intact mRNA intact Cleaving target miRNA Cleaving target mRNA
Mechanism Masking miRNA binding site in target
mRNA
Relieving translational repression Blocking translational process
Outcome Protein expression (mRNA level ) Protein expression
(mRNA level )
Protein expression (mRNA level )
Note: CdR represents coding region; miRNA and mRNA are underlined to highlight the difference
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approach defers from the conventional antisense technique
in the following two aspects, despite that they both are
entirely complementary to the target sequences. First, a
conventional antisense ODNs can be designed to target any
part of the protein-coding region of a gene (though the
sequences from the translation start codon are frequently
used), whereas a miR-Mask are limited to the target site of
a miRNA in the 3′UTR of a protein-coding gene. In other
words, the action of a miR-Mask depends on the basal
activity of the endogenous miRNA on the target mRNA.
Second, more importantly, a conventional antisense ODNs
binds to its target site in the coding region of a gene and
hinder the protein translation process, whereas a miR-Mask
bind to the 3′UTR and masks the target site of a miRNA so
as to block the action of the endogenous miRNA and
enhance protein translation. Thus, the two techniques
produce exactly opposite outcomes: one inhibits but the
other enhances gene expression. This expression-enhancing
action of miR-Mask is unique and could have many
applications. A comparison of the miR-Mask, the AMO,
and the conventional antisense ODN techniques are
summarized in Table 1 and illustrated in Fig. 3.
miRNA mimic techniques (miR-Mimic) With a rationale
similar to miR-Mask, in order to circumvent the problem of
non-gene specificity of miRNA actions, we developed a
technology utilizing synthetic, unnatural nucleic acids that
can bind to the unique sequence of target mRNAs in a
gene-specific manner and elicit posttranscriptional regula-
tory effects as a miRNA does [74]. We name this miRNA
Mimic technology (miR-Mimic). Two conditions must be
satisfied in order to generate a miRNA mimic: (1) a miR-
Mimic must be complementary to, only to, the 3′UTR of
the target gene to elicit miRNA action, so that that it
represses the target gene at the posttranscriptional level
with minimal effects on the mRNA level; and (2) the 3′
UTR of the target gene must contain a unique sequence
distinct from other genes to elicit gene-specific action. We
examine the application of the technique to cardiac
pacemaker genes HCN2 and HCN4. Following the rules,
we first identified a stretch of sequence in the 3′UTR
unique to the HCN2 (or HCN4) gene that is expectedly long
enough for miRNA action. Based on the unique sequence,
we designed a 22-nt miR-Mimic that at the 5′ end has eight
nucleotides (nucleotides 2–8) and at the 3′end has seven
nucleotides, complementary to the HCN2 (or HCN4)
sequence. These miR-Mimics produced substantial repres-
sion of HCN channel protein expression with concomitant
depression of pacemaker activities and reduction of heart
rate but with minimal effects on their mRNA levels. We
have also tested the miR-Mimics designed to target Bcl-2
and E2F, respectively, and observed remarkable suppres-
sion of tumor cell growth (unpublished data). The results
demonstrated a promise of utilizing the technology for
gene-specific repression of expression at the protein level
based on the principle of miRNA actions. The differences
among miR-Mimics and natural miRNAs and siRNAs are
listed in Table 2 and illustrated in Fig. 3.
Table 2 Comparisons among miR-Mimic, miRNA, and siRNA
miR-Mimic miRNA siRNA
Origin Artificial, synthetic Natural, endogenous Artificial, synthetic
Targeting Single mRNA Multiple mRNAs Single mRNA
Specificity Gene specific Non-gene specific Gene specific
Sequence-specific
Complementarity Partial to target mRNA (complementary
degree upon design)
Partial to target mRNA (complementary
degree by nature)
Full to target mRNA
Mechanism Translation inhibition mRNA cleavage Translation inhibition mRNA cleavage mRNA cleavage
Note: miRNA and mRNA are underlined to highlight the difference
Fig. 3 Upper panel: Schematic presentation of actions of miRNA-
masking antisense oligonucleotide (miR-Mask) compared with the
conventional antisense oligodeoxynucleotide (ODN) and antimiRNA
antisense inhibitor oligonucleotide (AMO) technologies. Synthetic
nucleic acids are introduced into the cells. Antisense ODNs bind to
the coding region of the target mRNA and hinder the translation
process; AMOs bind to the target miRNA, resulting in miRNA
cleavage; miR-Masks bind to the binding site of miRNAs in 3′UTR
of the target mRNA and prevent miRNAs from binding to the target
mRNA, leading to a relief of translational repression without affecting
miRNAs. Lower panel: Schematic presentation of actions of miRNA
mimic (miR-Mimic) compared with the miRNA and small interference
RNA (siRNA). Synthetic miR-Mimic and siRNA are introduced into the
cells and endogenous miRNA is synthesized by the cell. siRNAs bind to
the coding region of target miRNAs and cause mRNA cleavage;
miRNAs bind to 3′UTR of multiple target mRNAs and produce non-
gene-specific posttranscriptional repression to inhibit translation;
miR-Mimics bind to 3′UTR of unique target mRNAs and produce
gene-specific posttranscriptional repression to inhibit translation
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